Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations.
Read More
New COVID-19 Drug Therapy Developed by Canadian Biotech Start-up Headed for Phase III Clinical Trial Sponsored by the RI-MUHC
The reformulation of an existing generic drug could help neutralize the worse aspects of COVID.
Read More
